CAR T cells targeting the glycoprotein GD2 show potent antitumor efficacy in high-risk ependymoma models.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41289021.
- Also identified by DOI 10.1172/JCI193332 and PMC identifier 12807483.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Aggressive pediatric brain tumor models of ependymoma are highly sensitive to GD2-directed (CAR T) cell therapy.
Medical subject headings
- Ependymoma
- Gangliosides
- Brain Neoplasms
- Immunotherapy, Adoptive
- Receptors, Chimeric Antigen